https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Wed, 02 Sep 2026 20:07:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit Wed, 02 Sep 2026 20:07:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results Mon, 31 Aug 2026 21:02:23 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients · IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue · The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin responsea · A mean increase in hemoglobin of 1 g/dL at Week 1b and improvement in FACIT-Fatiguec score at Week 24 were observed in IMAAVY-treated patientsd Mon, 24 Aug 2026 22:26:56 GMT https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-global-classification-system-for-surgical-outcomes Peer-reviewed DISH Classification System establishes a standardized approach to reporting dehiscence, infection, seroma and hematoma across surgical specialties Mon, 24 Aug 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-global-classification-system-for-surgical-outcomes https://www.jnj.com/media-center/press-releases/johnson-johnson-publishes-new-future-of-digital-surgery-report-to-help-define-the-emerging-field-of-surgical-intelligence Drawing on insights from leaders across healthcare, technology, policy and investment, the report introduces a common framework for surgical intelligence and outlines the foundations required to operationalize it responsibly at scale. Tue, 18 Aug 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-publishes-new-future-of-digital-surgery-report-to-help-define-the-emerging-field-of-surgical-intelligence https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-monarch-quest-3-advancing-the-latest-in-robotically-assisted-bronchoscopy Introducing MONARCH™ QUEST 3, the latest software update for the MONARCH™ Platform, designed to enhance planning, navigation, and targeting in the early detection of lung cancer1-3. Mon, 17 Aug 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-monarch-quest-3-advancing-the-latest-in-robotically-assisted-bronchoscopy https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference Mon, 10 Aug 2026 20:27:25 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-wells-fargo-healthcare-conference Tue, 04 Aug 2026 20:05:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-wells-fargo-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnsons-executive-vice-president-jennifer-taubert-to-retire-tom-cavanaugh-appointed-evp-worldwide-chairman-innovative-medicine-effective-september Tue, 04 Aug 2026 12:46:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-executive-vice-president-jennifer-taubert-to-retire-tom-cavanaugh-appointed-evp-worldwide-chairman-innovative-medicine-effective-september https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-priority-review-as-potential-first-in-class-egfr-and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance Thu, 30 Jul 2026 12:30:03 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-priority-review-as-potential-first-in-class-egfr-and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation Wed, 29 Jul 2026 21:42:41 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset Wed, 29 Jul 2026 21:28:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset https://www.jnj.com/media-center/press-releases/johnson-johnson-introduces-monarch-platform-to-the-middle-east The launch of the first robotically-assisted bronchoscopy platform in the market offers new options for diagnosis and treatment of early-stage lung cancer First cases also mark the first clinical use of MONARCH™ QUEST AI-enabled navigation in the region. Tue, 28 Jul 2026 12:51:21 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-introduces-monarch-platform-to-the-middle-east https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-a-proposed-resolution-of-ovarian-talc-litigation Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining 76,000 Ovarian Talc Claims Mon, 27 Jul 2026 22:29:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-a-proposed-resolution-of-ovarian-talc-litigation https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma · Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma · Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey Thu, 23 Jul 2026 12:44:29 GMT https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-market-authorization-in-the-u-s-for-its-ottava-robotic-surgical-system Wed, 22 Jul 2026 11:01:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-market-authorization-in-the-u-s-for-its-ottava-robotic-surgical-system https://www.jnj.com/media-center/press-releases/depuy-synthes-acquires-expanding-innovations Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market Thu, 16 Jul 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-acquires-expanding-innovations https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-time-to-introduce-new-healthcare-champion-of-the-year-award • New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. • The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems. • Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026. Thu, 16 Jul 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-time-to-introduce-new-healthcare-champion-of-the-year-award https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2026 Wed, 15 Jul 2026 10:25:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • Wed, 15 Jul 2026 10:20:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-FDA-approval-for-the-Dual-Energy-Thermocool-Smarttouch-SF-platform · Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency energy together in a single catheter. · Integrated with the CARTO ecosystem, the platform gives physicians greater versatility to tailor treatment based on patient anatomy and case complexity.i Wed, 08 Jul 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-FDA-approval-for-the-Dual-Energy-Thermocool-Smarttouch-SF-platform https://www.jnj.com/media-center/press-releases/depuy-synthes-appoints-christina-zamarro-as-chief-financial-officer Mon, 29 Jun 2026 20:30:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-appoints-christina-zamarro-as-chief-financial-officer https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis · New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infections · To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY · IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG) Fri, 26 Jun 2026 16:45:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis https://www.jnj.com/media-center/press-releases/chmp-recommendation-advances-johnson-johnsons-tecvayli-teclistamab-plus-daratumumab-as-a-potential-standard-of-care-for-relapsed-refractory-multiple-myeloma Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus standard of care1 Pending approval, this novel complementary immunotherapy combination is positioned to delay disease progression for patients treated as early as second line, with 83% of patients alive at three years1 Fri, 26 Jun 2026 12:11:23 GMT https://www.jnj.com/media-center/press-releases/chmp-recommendation-advances-johnson-johnsons-tecvayli-teclistamab-plus-daratumumab-as-a-potential-standard-of-care-for-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-begins-enrollment-in-pivotal-studies-evaluating-first-of-its-kind-carotid-ivl-platform · U.S. IDE study program will evaluate the purpose-built Shockwave™ SkyRunner Carotid IVL System designed to address the challenges of calcification in carotid arteries prior to stenting · Clinical program is part of Johnson & Johnson’s plan to enhance treatment options for patients with carotid artery disease, which accounts for up to one-third of all strokes Thu, 25 Jun 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-begins-enrollment-in-pivotal-studies-evaluating-first-of-its-kind-carotid-ivl-platform